Valiant Laboratories Ltd. is significantly underperforming in key financial metrics compared to its peers in the Pharmaceuticals & Drugs sector. The company exhibits negative revenue growth, a negative EPS, and unfavorable profitability and valuation metrics, indicating financial distress. In contrast, several peers demonstrate strong growth, profitability, and attractive valuations, highlighting Valiant's challenges and the need for strategic reevaluation.

• • Valiant Laboratories shows negative revenue growth (-26.74%) and EPS (-0.4052), marking it as a sector underperformer.
• • Sun Pharmaceutical Industries and Dr. Reddy's Laboratories lead in profitability metrics with high ROE (16.13% and 21.76% respectively).
• • Cipla presents as a strong value pick with a low PE ratio (23.73) and solid profitability metrics.